The paradigm shift in the diagnosis of Alzheimer's disease

doi:10.3969/j.issn.1672-6731.2026.02.001

Abstract

Abstract: The diagnostic criteria for Alzheimer's disease(AD) has undergone the fundamental shift, moving from clinical symptom-based approach to the focus on precise pathological changes. This paper focuses on the diagnostic advances and future prospects of cerebrospinal fluid biomarkers, blood biomarkers, and molecular imaging biomarkers for Alzheimer's disease, aiming to provide guidance for the early and accurate diagnosis of the disease.

Key words: Alzheimer disease, Amyloid beta-peptides, Tau proteins, Positron-emission tomography, Review

摘要： 阿尔茨海默病的诊断标准业已发生根本性转变，实现从临床症状到精准病理变化的重心转移。本文聚焦阿尔茨海默病脑脊液标志物、血液标志物、分子影像学标志物的诊断进展及未来展望，以期对疾病的早期精准诊断提供指导。

关键词: 阿尔茨海默病, 淀粉样β肽类, tau蛋白质类, 正电子发射断层显像术, 综述

CLC Number:

R741

JI Yong, WANG Pan. The paradigm shift in the diagnosis of Alzheimer's disease[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2026, 26(2): 105-108.

纪勇, 王盼. 阿尔茨海默病诊断范式的转变[J]. 中国现代神经疾病杂志, 2026, 26(2): 105-108.

/ / Recommend / Download Citations

URL: https://journal11.magtechjournal.com/cjcnn/EN/10.3969/j.issn.1672-6731.2026.02.001

https://journal11.magtechjournal.com/cjcnn/EN/Y2026/V26/I2/105

References

[1] Gustavsson A, Norton N, Fast T, Frölich L, Georges J, Holzapfel D, Kirabali T, Krolak-Salmon P, Rossini PM, Ferretti MT, Lanman L, Chadha AS, van der Flier WM.Global estimates on the number of persons across the Alzheimer's disease continuum[J]. Alzheimers Dement, 2023, 19:658-670.
[2] Gan J, Zeng Y, Huang G, Wang XD, LüY, Niu J, Meng X, Cai P, Li X, Li Y, Shen L, You Y, Gang B, Tang Y, Lv Y, Ren Z, Liu S, Ji Y.The updated prevalence and risk factors of dementia in old adults in China:a cross-sectional study[J]. JAlzheimers Dis, 2024, 102:1209-1223.
[3] Jack CR Jr, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, Hansson O, Ho C, Jagust W, McDade E, Molinuevo JL, Okonkwo OC, Pani L, Rafii MS, Scheltens P, Siemers E, Snyder HM, Sperling R, Teunissen CE, Carrillo MC.Revised criteria for diagnosis and staging of Alzheimer's disease:Alzheimer's Association Workgroup[J]. Alzheimers Dement, 2024, 20:5143-5169.
[4] Barthélemy NR, Bateman RJ, Hirtz C, Marin P, Becher F, Sato C, Gabelle A, Lehmann S.Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identification[J]. Alzheimers Res Ther, 2020, 12:26.
[5] Mendes AJ, Ribaldi F, Lathuiliere A, Ashton NJ, Janelidze S, Zetterberg H, Scheffler M, Assal F, Garibotto V, Blennow K, Hansson O, Frisoni GB.Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus ptau181 and p-tau231 in a memory clinic cohort[J]. J Neurol, 2024, 271:2053-2066.
[6] Amft M, Ortner M, Eichenlaub U, Goldhardt O, Diehl-Schmid J, Hedderich DM, Yakushev I, Grimmer T.The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort[J]. Alzheimers Res Ther, 2022, 14:60.
[7] Pahlke S, Kahale LA, Mahinrad S, Sousa-Pinto B, Vieira RJ, McAteer MB, Claessen T, Contador J, Hofmann A, Kuchenbecker LA, Machado LS, Warmenhoven N, Yakoub Y, Palmqvist S, Schindler SE, Teunissen C, Whitson HE, Zetterberg H, Edelmayer R, Tampi MP.Blood-based biomarkers for detecting Alzheimer's disease pathology in cognitively impaired individuals within specialized care settings:a systematic review and meta-analysis[J]. Alzheimers Dement, 2025, 21:e70828.
[8] Catania M, Battipaglia C, Perego A, Salvi E, Maderna E, Cazzaniga FA, Rossini PM, Marra C, Vanacore N, Redolfi A, Perani D, Spadin P, Cotelli M, Cappa S, Caraglia N, Tiraboschi P, Tagliavini F, Di Fede G.Exploring the ability of plasma pTau217, pTau181 and beta-amyloid in mirroring cerebrospinal fluid biomarker profile of mild cognitive impairment by the fully automated Lumipulse^®platform[J]. Fluids Barriers CNS, 2025, 22:9.
[9] Warmenhoven N, SalvadóG, Janelidze S, Mattsson-Carlgren N, Bali D, Orduña Dolado A, Kolb H, Triana-Baltzer G, Barthélemy NR, Schindler SE, Aschenbrenner AJ, Raji CA, Benzinger TLS, Morris JC, Ibanez L, Timsina J, Cruchaga C, Bateman RJ, Ashton N, Arslan B, Zetterberg H, Blennow K, Pichet Binette A, Hansson O.A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests[J]. Brain, 2025, 148:416-431.
[10] Aarsland D, Sunde AL, Tovar-Rios DA, Leuzy A, Fladby T, Zetterberg H, Blennow K, Tan K, De Santis G, Yakoub Y, Arslan B, Huber H, Pola I, Grötschel L, Di Molfetta G, Skjellegrind HK, Selbaek G, Ashton NJ.Prevalence of Alzheimer's disease pathology in the community[J]. Nature, 2026, 650:182-186.
[11] Barthélemy NR, SalvadóG, Schindler SE, He Y, Janelidze S, Collij LE, Saef B, Henson RL, Chen CD, Gordon BA, Li Y, La Joie R, Benzinger TLS, Morris JC, Mattsson-Carlgren N, Palmqvist S, Ossenkoppele R, Rabinovici GD, Stomrud E, Bateman RJ, Hansson O.Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests[J]. Nat Med, 2024, 30:1085-1095.
[12] Janelidze S, Barthélemy NR, SalvadóG, Schindler SE, Palmqvist S, Mattsson-Carlgren N, Braunstein JB, Ovod V, Bollinger JG, He Y, Li Y, Raji CA, Morris JC, Holtzman DM, Ashton NJ, Blennow K, Stomrud E, Bateman RJ, Hansson O.Plasma phosphorylated tau 217 and Aβ42/40 to predict early brain Aβ accumulation in people without cognitive impairment[J]. JAMA Neurol, 2024, 81:947-957.
[13] Palmqvist S, Whitson HE, Allen LA, Suarez-Calvet M, Galasko D, Karikari TK, Okrahvi HR, Paczynski M, Schindler SE, Teunissen CE, Zetterberg H, Carrillo MC, Edelmayer RM, Mahinrad S, McAteer MB, Kahale LA, Pahlke S, Tampi MP.Alzheimer's Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings[J]. Alzheimers Dement, 2025, 21:e70535.
[14] Frisoni GB, Hansson O, Nichols E, Garibotto V, Schindler SE, van der Flier WM, Jessen F, Villain N, Arenaza-Urquijo EM, Crivelli L, Fortea J, Grinberg LT, Ismail Z, Minoshima S, Ossenkoppele R, Zetterberg H, Petersen RC, Dubois B.New landscape of the diagnosis of Alzheimer's disease[J]. Lancet, 2025, 406:1389-1407.
[15] Reiman EM, Alexander RC, Langbaum JB, Aisen PS, Ashton N, Atri A, Barbarino P, Byrd GS, Feldman HH, Fowler NR, Ghisays V, Grill JD, Hassenstab J, Heaton GR, Herring WL, Jack CR Jr, Johnson SC, Karlawish J, Keach NL, Kivipelto M, Krumholz HM, Largent EA, MaGee-Rodgers T, McDade E, Mielke MM, Molina-Henry D, Petersen RC, Rabinovici GD, Ritchie C, Schindler SE, Sperling RA, Suárez-Calvet M, Vradenburg G, Weiner MW, Welsh-Bohmer KA, Zetterberg H, Zuendel MT, Mattke S, Cummings JL.A path to preventing cognitive impairment due to Alzheimer's disease:initiatives beginning in the USA[J]. Lancet Neurol, 2026, 25:268-278.
[16] Karur P, Kaldas M, Ramesh Babu YS, Parmar MS.Phosphorylated tau biomarkers in Alzheimer's disease:from early detection to clinical potential.A comprehensive review[J]. Mol Neurobiol, 2026, 63:389.
[17] Groot C, Smith R, Collij LE, Mastenbroek SE, Stomrud E, Binette AP, Leuzy A, Palmqvist S, Mattsson-Carlgren N, Strandberg O, Cho H, Lyoo CH, Frisoni GB, Peretti DE, Garibotto V, La Joie R, Soleimani-Meigooni DN, Rabinovici G, Ossenkoppele R, Hansson O.Tau positron emission tomography for predicting dementia in individuals with mild cognitive impairmen[tJ]. JAMA Neurol, 2024, 81:845-856.
[18] Ioannou K, Bucci M, Tzortzakakis A, Savitcheva I, Nordberg A, Chiotis K;Alzheimer's Disease Neuroimaging Initiative.Tau PET positivity predicts clinically relevant cognitive decline driven by Alzheimer's disease compared to comorbid cases;proof of concept in the ADNI study[J]. Mol Psychiatry, 2025, 30:587-599.
[19] Tang Y, Xiong X, Tong G, Yang Y, Zhang H.Multimodal diagnosis model of Alzheimer's disease based on improved transforme[rJ]. Biomed Eng Online, 2024, 23:8.
[20] Zheng X, Worhunsky P, Liu Q, Guo X, Chen X, Sun H, Zhang J, Toyonaga T, Mecca AP, O'Dell RS, van Dyck CH, Angarita GA, Cosgrove K, D'Souza D, Matuskey D, Esterlis I, Carson RE, Radhakrishnan R, Liu C.Generating synthetic brain PETimages of synaptic density based on MR T1 images using deep learning[J]. EJNMMI Phys, 2025, 12:30.
[21] Rikken RM, Yaqub M, Coomans EM, Dicks E, van der Vlies AE, Windhorst AD, Boellaard R, Pijnenburg YAL, Vijverberg EGB, van de Giessen E.Neuroinflammation PET and long-term cognition and survival in symptomatic Alzheimer's disease[J]. Alzheimers Res Ther, 2025, 17:275.
[22] Zetterberg H, Bendlin BB.Biofluid biomarkers in Alzheimer's disease and other neurodegenerative dementias[J]. Nature, 2026, 650:49-59.
[23] Li D, Liu K, Li D, Brunger A, Liu C, BurréJ, Diao J.α-synuclein condensation in synaptic vesicle function and synucleinopathies[J]. Trends Cell Biol, 2026, 36:57-70.

Please choose a citation manager

Content to export